Zydus Lifesciences gets USFDA nod for generic acne-treating drug

The approval granted by the US Food and Drug Administration (USFDA) is for Minocycline Hydrochloride extended-release tablets of strengths 55 mg, 65 mg, and 115 mg, Zydus Lifesciences said in a regulatory filing.

Zydus Lifesciences gets USFDA nod for generic acne-treating drug
The tablet is used for treatment of moderate to severe acne in people aged 12 years and above, image- unsplash

Zydus Lifesciences on Monday said it has received final approval from the US health regulator for its generic antibiotic Minocycline Hydrochloride extended-release tablets used for treatment of moderate to severe acne.

The approval granted by the US Food and Drug Administration (USFDA) is for Minocycline Hydrochloride extended-release tablets of strengths 55 mg, 65 mg, and 115 mg, Zydus Lifesciences said in a regulatory filing.

The tablet is used for treatment of moderate to severe acne in people aged 12 years and above.

The product will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, the company said.

Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.

 

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

RECOMMENDED STORIES

https://www.zeebiz.com/personal-finance/photo-gallery-top-7-flexi-cap-sip-mutual-funds-with-highest-best-xirr-return-in-1-year-calculator-inr-rs-20000-monthly-investment-in-no-1-scheme-has-generated-302-lakh-bse-nifty-500-motilal-bank-hsbc-of-india-aum-nav-333620

Top 7 Flexi Cap Mutual Funds With up to 52% SIP Return in 1 Year: Rs 20,000 monthly SIP investment in No. 1 fund has generated Rs 3.02 lakh; know about others too

https://www.zeebiz.com/personal-finance/photo-gallery-sukanya-samriddhi-yojana-ssy-and-ppf-public-provident-fund-rs-100000-per-year-investment-for-15-years-which-can-create-larger-corpus-on-maturity-calculate-331817

Sukanya Samriddhi Yojana vs PPF: Rs 1 lakh/year investment for 15 years; which can create larger corpus on maturity?

https://www.zeebiz.com/personal-finance/photo-gallery-top-7-index-sip-mutual-funds-with-highest-best-xiir-returns-in-3-years-calculator-no-1-scheme-has-turned-inr-rs-22222-monthly-investment-into-1626892-large-mid-small-cap-nifty-50-bse-motilal-uti-333867

Top 7 Index Mutual Funds With Best SIP Returns in 3 Years: No. 1 scheme has turned Rs 22,222 monthly SIP investment into Rs 16,26,892; see others' performance

https://www.zeebiz.com/personal-finance/photo-gallery-top-7-gold-etfs-with-best-highest-cagr-annual-returns-in-3-years-calculator-no-1-mutual-fund-has-converted-inr-rs-700000-into-1079960-lic-hdfc-uti-invesco-fof-domestic-pure-price-benchmark-333814

Top 7 Gold ETFs With Best Returns in 3 Years: No.1 ETF has converted Rs 7 lakh investment into Rs 10.80 lakh; know how others have fared

https://www.zeebiz.com/personal-finance/photo-gallery-rs-5500000-home-loan-emi-vs-55-lakh-sip-mutual-fund-investment-calculator-which-can-be-faster-route-to-arrange-money-for-6100000-home-interest-rate-repayment-calculations-333443

Rs 55 lakh Home Loan vs Rs 55 lakh SIP investment: Which can be faster route to arrange money for Rs 61 lakh home? Know here

https://www.zeebiz.com/personal-finance/photo-gallery-sip-vs-ppf-public-provident-fund-compare-rs-120000-lakh-per-year-investment-over-15-years-to-determine-which-option-creates-higher-corpus-for-your-financial-goals-333092

SIP vs PPF: Rs 1,20,000 lakh per year investment for 15 years; which can create higher corpus?

Written By: PTI
Updated: Mon, Jun 19, 2023
04:58 PM IST
Mumbai, PTI
RELATED NEWS
Zydus Lifesciences gets USFDA nod to produce prostrate cancer drug Zydus Lifesciences gets USFDA nod to produce prostrate cancer drug
Zydus gets USFDA nod to produce generic prostate cancer drug Zydus gets USFDA nod to produce generic prostate cancer drug
Zydus Lifesciences to acquire Sterling Biotech's API business for Rs 84 crore Zydus Lifesciences to acquire Sterling Biotech's API business for Rs 84 crore

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x